Clik here to view.
MPEG LA、査読論文のNucleic Acid Therapeutics誌への掲載を発表
デンバー （ビジネスワイヤ） — 技術ライセンシングの世界的リーダー企業MPEG LAは本日、Nucleic Acid Therapeutics誌の2019年10月号に、MPEG LA専有のリガンド指向型多重ペイロード・オリゴヌクレオチド送達プラットフォームIncrescent Therapeutics™に関する査読論文が掲載されたと発表しました。 MPEG...
View ArticleClik here to view.
GRAIL Announces Positive Validation Data for Its Multi-Cancer Early Detection...
MENLO PARK, Calif. GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced new data validating the performance of its investigational multi-cancer early detection...
View ArticleClik here to view.
CORRECTING and REPLACING GRAIL Announces Positive Validation Data for Its...
MENLO PARK, Calif. Ninth paragraph, first sentence of the release should read: In the group of more than 20 cancer types, the overall detection rate at 99.3 percent specificity was 55 percent...
View ArticleClik here to view.
MPEG LA宣布《核酸治疗药物》发表同行评议论文
丹佛 (美国商业资讯)–世界领先的技术许可证提供商MPEG LA 今天宣布，《核酸治疗药物》(Nucleic Acid Therapeutics) 2019年10月刊发表一篇有关MPEG LA专利Increscent Therapeutics™配体导向多负载寡聚核苷酸给药平台的同行评议的论文。 MPEG LA总裁兼首席执行官Larry Horn表示：“MPEG...
View ArticleClik here to view.
Tej Kohli Foundation advocates a scalable, accessible and affordable...
LONDON On World Sight Day, the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is...
View ArticleClik here to view.
Clik here to view.
Tej Kohli基金会倡导一种可扩展、易获取且平价的技术解决方案来终结全球角膜失明
伦敦 (美国商业资讯)–在世界视力日，Tej Kohli基金会表示，必须专注于新技术，才能加快在全世界终结可治愈角膜失明的全球使命。基金会目前正在资助临床试验和一种“液态生物合成”解决方案的开发，该解决方案有望提供易获取、可扩展且平价的角膜失明解决方案，这种解决方案对于全世界1200万角膜失明患者中的许多人是至关重要的。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
美国项目管理协会公布过去50年50大最具影响力项目
费城 (美国商业资讯)–美国项目管理协会(PMI)今天发布最具影响力项目名单，评出过去50年最具影响力的50个著名项目。这是PMI首次公布此类排名，表彰了过去50年最具影响力的项目，突显了项目管理如何帮助将这些想法变为现实。...
View ArticleClik here to view.
Clik here to view.
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO®...
LONDON Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12...
View ArticleClik here to view.
Kraig Biocraft Laboratories Completes Rearing of First Production Batch of...
ANN ARBOR, Mich. Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its operations team at its Vietnamese...
View ArticleClik here to view.
Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing...
SAN DIEGO Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 –...
View ArticleClik here to view.
路胜生物与迈杰（苏州）在中国合作开发领先的癌症检测
苏州 新加坡领先的基因组医学公司路胜生物苏州有限公司（简称路胜）宣布将与迈杰转化医学研究（苏州）有限公司 【简称（迈杰（苏州）】建立战略合作伙伴关系，共同开发癌症检测，包括伴随诊断，这一举动不仅造福广大癌症患者，而且为新药研发公司提供更多的创新合作机会。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
MEDx (Suzhou) and Lucence Partner to Co-Develop Cutting-Edge Cancer-Care Tests
SUZHOU, China MEDx (Suzhou) Translational Medicine, and Singapore-based Lucence – a leading genomic medicine company – today announced an agreement to pursue a strategic partnership in China to...
View ArticleClik here to view.
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first,...
View ArticleClik here to view.
Kraig Biocraft Laboratories Completes Scale-Up Production Cycle of...
ANN ARBOR, Mich. Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that Prodigy Textiles, the Company’s Vietnamese...
View ArticleClik here to view.
EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
路胜生物完成由IHH Healthcare领投的2千万美元A轮投资，用于推动液体活检技术，进行多种癌症早期检测
新加坡 (美国商业资讯)– 路胜生物(Lucence)，发明用于癌症筛查, 治疗选择的血液检测的基因组医学公司，今天宣布完成2千万美元A轮融资。此轮融资的领投者是全球最大的综合私人医疗保健集团之一IHH Healthcare。参投者包括新加坡创新机构(SGInnovate)，以及现有投资者淡马锡控股(Temasek Holdings) 旗下的海丽凯资本管理公司(Heliconia...
View ArticleClik here to view.
Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid...
SINGAPORE Lucence, a genomic medicine company that invents blood-based tests for cancer screening and treatment selection, announced today the close of USD $20 million in Series A funding. The round...
View ArticleClik here to view.
Phenomics Health Inc. 收购专利药物代谢组技术
密西根州安娜堡 (美国商业资讯)–基于生物信息学平台的精准医学公司Phenomics Health Inc.今天宣布，其已收购总部位于美国田纳西州富兰克林的Precera Bioscience公司的专利药物代谢组技术组合。 Phenomics Health计划将该新技术与自身的专利先进药物基因组平台相整合，在患者对用药的潜在和实际应答方面，向医疗保健提供者提供比现有技术更完整的图景。...
View Article